Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte signs strategic platform licence with Catamaran Bio

Wed, 04th Jan 2023 08:56

(Alliance News) - MaxCyte Inc on Wednesday said it signed a strategic platform licence with biotechnology company Catamaran Bio Inc.

MaxCyte, the US commercial cell-engineering company with an office in Cheshire, England, said the platform licence was to support Catamaran Bio's CAR-NK cell therapy programmes, allowing it to use MaxCyte's Flow Electroporation technology and ExPERT platform.

ExPERT delivers essential high-end performance for enabling the next wave of biological and cellular therapeutics, according to MaxCyte.

It will receive platform licensing fees and programme-related revenue in exchange.

"At MaxCyte, we are passionate about driving the discovery, development and manufacturing of next-generation, cell-based medicines to tackle complex diseases and cancer," said Doug Doerfler, chief executive officer at MaxCyte. "We are excited to support Catamaran with the advancement of their pipeline of differentiated CAR-NK cell therapies into and through the clinic."

Catamaran Bio's business model focuses on developing novel, off-the-shelf chimeric antigen receptor CAR-NK cell therapies to treat a broad range of cancers, particularly involving solid tumours.

The licence is alongside having developed its integrated suite of technologies platform Tailwind to engineer, expand and process NK cells into safe and effective cell therapy products for multiple cancer types.

Shares in MaxCyte were up 1.3% to 443.00 pence each in London on Wednesday morning.

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Apr 2020 16:59

MaxCyte Annual Loss Widens As Carma Investment Increases

MaxCyte Annual Loss Widens As Carma Investment Increases

Read more
9 Apr 2020 14:54

UK TRADING UPDATE SUMMARY: Naked Wines, Distil Get Bar-Closure Boost

UK TRADING UPDATE SUMMARY: Naked Wines, Distil Get Bar-Closure Boost

Read more
21 Feb 2020 11:53

MaxCyte to consolidate stock to single trading line

(Sharecast News) - Life sciences company MaxCyte announced the consolidation of its two lines of common stock into a single unrestricted line of common stock on Friday.

Read more
20 Jan 2020 10:58

MaxCyte 'exceptionally positive' following strong FY trading performance

(Sharecast News) - Clinical-stage life sciences company MaxCyte told investors on Monday that its board was "exceptionally positive" of the group's future following a stellar year.

Read more
20 Jan 2020 09:00

MaxCyte Shares Rise As It Expects To Report 30% Increase In Revenue

MaxCyte Shares Rise As It Expects To Report 30% Increase In Revenue

Read more
4 Dec 2019 16:14

MaxCyte inks new development agreement with KSQ Therapeutics

(Sharecast News) - Cell-based therapeutics and life sciences company MaxCyte has entered into a new development and commercialisation agreement with its existing partner KSQ Therapeutics, it announced on Wednesday.

Read more
4 Dec 2019 11:50

MaxCyte Shares Rise As It Signs Development Deal With KSQ Therapeutics

MaxCyte Shares Rise As It Signs Development Deal With KSQ Therapeutics

Read more
21 Nov 2019 18:55

MaxCyte Inks Non-Exclusive Licence Agreement With Vor Biopharma

MaxCyte Inks Non-Exclusive Licence Agreement With Vor Biopharma

Read more
21 Nov 2019 16:40

MaxCyte strikes deal with oncology company Vor Biopharma

(Sharecast News) - Cell-based therapies and life sciences company MaxCyte announced a clinical and commercial licence agreement with oncology company Vor Biopharma on Thursday, under which Vor would use MaxCyte's 'Flow Electroporation' technology to produce engineered hematopoietic stem cells (eHSCs), and initiate investigational new drug-enabling studies to accelerate its progress towards the clinic.

Read more
24 Oct 2019 12:53

MaxCyte Advances Phase I Clinical Trial Of Cancer Drug MCY-M11

MaxCyte Advances Phase I Clinical Trial Of Cancer Drug MCY-M11

Read more
7 Oct 2019 12:23

MaxCyte And Editas Ink Five Medicine Licence Deal, EDIT-301 Included

MaxCyte And Editas Ink Five Medicine Licence Deal, EDIT-301 Included

Read more
18 Sep 2019 11:59

MaxCyte Interim Rises Revenue But Loss Widens On CARMA Investment

(Alliance News) - Life sciences company MaxCyte Inc on Wednesday reported first half revenue growth but its loss widened as expenses soared.In the six months to June 30, the firm's rose

Read more
11 Sep 2019 16:04

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 12 SeptemberĀ WM Morrison SupermarketsHalf Year ResultsBrooks MacdonaldFull Year

Read more
17 Jul 2019 13:43

MaxCyte Progresses On MCY-M11 Development As Interim Revenue Rises

(Alliance News) - MaxCyte Inc on Wednesday reported double-digit revenue growth in the first half of 2019 and expects to see continued progress throughout the second half of the year.The is

Read more
26 May 2019 21:53

Sunday share tips: IQE, MaxCyte

(Sharecast News) - In his 'Inside the City' column for The Sunday Times, Ben Woods looked at the effect of Donald Trump's posturing against Huawei on the chipmaking industry - particularly, wafer semiconductor technology minnow IQE.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.